December 23, 2011
A cancer drug company founded by UCSF Professor Kevan Shokat, PhD, has been acquired by Japan-based Takeda Pharmaceuticals in an effort to add two novel drug projects to Takeda’s pipeline of potential oncology therapies.
Shokat, who chairs the UCSF Department of Cellular and Molecular Pharmacology, launched Intellikine in 2007 to translate his UCSF kinase research into the development of small-molecule drugs. Kinases are enzymes that are known to regulate the majority of cellular pathways. The Intellikine therapies specifically target the PI-3 kinase (PI3K) pathway – a key target in cancer biology due to its impact on a wide array of cellular functions, including cell growth, proliferation and survival.